Alerts
Staying Healthy During Influenza Season

The University of Kansas Health System is experiencing a high volume of patients seeking care for influenza and other respiratory illnesses. Whether you plan to visit the health system or not, learn how to keep yourself healthy.

Modified Hours for Martin Luther King Jr. Day

In recognition of the upcoming Martin Luther King Jr. Day holiday, some of The University of Kansas Cancer Center’s offices will have modified hours on Monday, January 19, 2026.

Skip Navigation

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon alpha-2b for Resected High-Risk Melanoma.

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT01274338

Study #:
12935

Start Date:
Nov 30, 2011

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT01274338

View Complete Trial Details & Eligibility at ClinicalTrials.gov